Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Advanced Non-small Cell Lung Cancer
NCT02582125Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2016
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Ono Pharmaceutical. Started Jan 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02582125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02582125.